{"id":859274,"date":"2025-06-10T16:33:42","date_gmt":"2025-06-10T20:33:42","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/xilio-therapeutics-appoints-akintunde-bello-ph-d-to-its-board-of-directors\/"},"modified":"2025-06-10T16:33:42","modified_gmt":"2025-06-10T20:33:42","slug":"xilio-therapeutics-appoints-akintunde-bello-ph-d-to-its-board-of-directors","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/xilio-therapeutics-appoints-akintunde-bello-ph-d-to-its-board-of-directors\/","title":{"rendered":"Xilio Therapeutics Appoints Akintunde Bello, Ph.D., to its Board of Directors"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">WALTHAM, Mass., June  10, 2025  (GLOBE NEWSWIRE) &#8212; Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced the appointment of Akintunde (Tunde) Bello, Ph.D., to the company\u2019s board of directors.<\/p>\n<p align=\"justify\">\u201cTunde is an accomplished leader with a strong track record of successfully developing novel therapies across a broad range of therapeutic areas, including several important cancer immunotherapies for anti-CTLA-4, PD-1 and T-cell engager through all stages of development, and I am thrilled to welcome him to the board,\u201d said Paul Clancy, chair of the board of directors of Xilio Therapeutics. \u201cWith over 25 years of experience in oncology research and development, focused on translational medicine and clinical pharmacology at BMS and Pfizer, we look forward to benefitting from Tunde\u2019s extensive expertise as we advance toward the clinic with XTX501, our masked PD-1\/IL-2 bi-specific, and our bi-specific and tri-specific masked T cell engager programs.\u201d<\/p>\n<p align=\"justify\">\u201cXilio\u2019s innovative approach to developing tumor-activated immuno-oncology therapies presents an exciting opportunity to advance novel molecules, which hold the potential to overcome the limitations of current cancer treatments,\u201d said Dr. Bello. \u201cI am honored to join Xilio\u2019s board of directors at this important time and look forward to contributing to Xilio\u2019s efforts to meaningfully improve outcomes for patients while minimizing systemic toxicities.\u201d<\/p>\n<p>\n        <strong>Akintunde Bello, Ph.D.<\/strong>\n      <\/p>\n<p align=\"justify\">Dr. Bello brings more than 25 years of oncology drug development and leadership experience to Xilio, with deep expertise in early translational medicine and clinical pharmacology across complex biologics and immunotherapies, including anti-CTLA-4 and PD-1 checkpoint inhibitors, T cell engagers and tumor-selective molecules. He most recently served as senior vice president, head of clinical pharmacology, pharmacometrics and bioanalysis at Bristol Myers Squibb Company (BMS) until his retirement in 2025. While at BMS, Dr. Bello oversaw clinical pharmacology and pharmacometrics across multiple therapeutic areas. Prior to BMS, Dr. Bello spent more than a decade with Pfizer Inc. (Pfizer), where he was responsible for overseeing clinical pharmacology for Pfizer\u2019s late-stage oncology development programs. Dr. Bello received a B.Sc. in biomedical sciences from Portsmouth Polytechnic, an M.Sc. in instrumentation and analytical science from University of Manchester and a Ph.D. in pharmaceutical sciences from King\u2019s College, University of London.<\/p>\n<p>\n        <strong>About Xilio Therapeutics<\/strong>\n      <\/p>\n<p align=\"justify\">Xilio Therapeutics is a clinical-stage biotechnology company discovering and developing tumor-activated, or masked, immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is leveraging its proprietary platform to advance a pipeline of novel, tumor-activated I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment. Learn more by visiting <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=lY9C7xNxf4dGuBQICoPZSlblvZtS8VVd7CMvfPrpyNiHi_bNJ1R0PgJ-JzFC5lKPhr-u8fTH-s0yHnPxn4OXvb3YKNyrou8DSa-3-bPrW4M=\" rel=\"nofollow\" target=\"_blank\">www.xiliotx.com<\/a> and follow us on LinkedIn (<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Kp6zbDDlNkKq32aGLY4F5xQIHgwbe8LVlf-SriOUbJlstdX-TiibCryAURXpFapvRv-qhMnCI2bu1p7g9z_PxrzwUWT96OIKMIfd31caspPK9vVU_xIPlRUpPrryADEw\" rel=\"nofollow\" target=\"_blank\">Xilio Therapeutics, Inc<\/a>).<\/p>\n<p align=\"justify\">\n        <strong>Cautionary Note\u00a0Regarding Forward-Looking Statements<\/strong>\n      <\/p>\n<p align=\"justify\">This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding achievement of key milestones; and the potential benefits of any of Xilio\u2019s current or future product candidates in treating patients; and Xilio\u2019s strategy, goals, business plans and focus. The words \u201caim,\u201d \u201cmay,\u201d \u201cwill,\u201d \u201ccould,\u201d \u201cwould,\u201d \u201cshould,\u201d \u201cexpect,\u201d \u201cplan,\u201d \u201canticipate,\u201d \u201cintend,\u201d \u201cbelieve,\u201d \u201cestimate,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cpotential,\u201d \u201ccontinue,\u201d \u201cseek,\u201d \u201ctarget\u201d and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management\u2019s current expectations and beliefs and are subject to a number of important risks, uncertainties and other factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, general market conditions; risks and uncertainties related to ongoing and planned research and development activities, including initiating, conducting or completing preclinical studies and clinical trials and the timing and results of such preclinical studies or clinical trials; the delay of any current or planned preclinical studies or clinical trials or the development of Xilio\u2019s current or future product candidates; Xilio\u2019s ability to obtain and maintain sufficient preclinical and clinical supply of current or future product candidates; Xilio\u2019s advancement of multiple early-stage immune cell engager programs; interim or preliminary preclinical or clinical data or results, which may not be replicated in or predictive of future preclinical or clinical data or results; Xilio\u2019s ability to successfully demonstrate the safety and efficacy of its product candidates and gain approval of its product candidates on a timely basis, if at all; results from preclinical studies or clinical trials for Xilio\u2019s product candidates, which may not support further development of such product candidates; actions of regulatory agencies, which may affect the initiation, timing and progress of current or future clinical trials; Xilio\u2019s ability to obtain, maintain and enforce patent and other intellectual property protection for current or future product candidates; Xilio\u2019s ability to obtain and maintain sufficient cash resources to fund its operations; the impact of international trade policies on Xilio\u2019s business, including U.S. and China trade policies; Xilio\u2019s ability to maintain its clinical trial collaboration with Roche to develop vilastobart in combination with atezolizumab; and Xilio\u2019s ability to maintain its collaboration and partnership agreements with Gilead and AbbVie. These and other risks and uncertainties are described in greater detail in the sections entitled \u201cRisk Factor Summary\u201d and \u201cRisk Factors\u201d in Xilio\u2019s filings with the U.S. Securities and Exchange Commission (SEC), including Xilio\u2019s most recent Quarterly Report on Form\u00a010-Q and any other filings that Xilio has made or may make with the SEC in the future. Any forward-looking statements contained in this press release represent Xilio\u2019s views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Except as required by law, Xilio explicitly disclaims any obligation to update any forward-looking statements.<\/p>\n<p>This press release contains hyperlinks to information that is not deemed to be incorporated by reference in this press release.<\/p>\n<p>\n        <strong>Investor and Media Contact\u202f\u00a0<\/strong><\/p>\n<p>Scott Young\u00a0<br \/>Vice President, Investor Relations and Corporate Communications\u00a0<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=h7Kv1ACtvIOX5f6ZKgDnF2IiOu8VcNmN1qe_jmoOoR0dc05j-eXA_RprYyGdss2lhq5QthMyIUm6aj_8USpPPJDQ-1lKgUOizo6OlRoUy_1mj_5tYSkv5NoyAjY5CBvn1jw9h0WksBSv_fkocrOqkNhvCvdoAa2sRAFMu701DtsZy5_nMi8T_tVcaiW6DEZiv1sWqgmhvpCtMTyVz2VBvI_OX9zLjX11b30fEODhsovT2NJPaeGsFFcQsNbCZpn-_uJ2etdD8ZUo_gB4mDKVffhdWXHdCg3Sgg7vGzbKHpYN9tQX3V5-Z3_DRQ_Byxe_hwOad_uWCgAV19d2hHuMu-0R-22_aUJI132suJLOzpk3h-bPW-kRhkzLot6yAqDCCsG2nvudFc4zceDfLyyXA4Ebk9DFpV39KqJ3ia5EFqtnVAu5sGJuDkAVCdN-nxUNNw9iPAc42YZ4gxlVN6cm2x0G0O48UdC_lhkuthLQzlNX44fEkeDHX1sZr7YuQQyn6nzNV4uuCM9Th1QfJTHGrtJ-JRbPCNjwThtKU8jn0nmlbF4vwaAVKQvTcV1flCmajQEQ7jXXc4_91_pLpzSGsJk1mHdPtx6y45ET9vLDgrBSISSj3Qg-3PngltivK3t5Xe2-PoirIaAGko3Cj_G_uV3lFWnUPnkJNEbIeQ-8n-voaV5oZimVvrcllelWv1XoKENEKNnW8PwuVg_s33kDafYn2WFnM0TRqyV27e0yBd46achnyV-EPZ351nDPvk0F7RpJb5mNvEC0w-UXJyAteQ==\" rel=\"nofollow\" target=\"_blank\">investors@xiliotx.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ2NjQyMSM2OTg0NTg4IzIyMDk4MDQ=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/MzEzYjcyYjAtNWQ1NS00NjcwLWIzNzItY2U4OTQ2NmM3NmVkLTEyMjEzNTctMjAyNS0wNi0xMC1lbg==\/tiny\/Xilio-Therapeutics-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>WALTHAM, Mass., June 10, 2025 (GLOBE NEWSWIRE) &#8212; Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced the appointment of Akintunde (Tunde) Bello, Ph.D., to the company\u2019s board of directors. \u201cTunde is an accomplished leader with a strong track record of successfully developing novel therapies across a broad range of therapeutic areas, including several important cancer immunotherapies for anti-CTLA-4, PD-1 and T-cell engager through all stages of development, and I am thrilled to welcome him to the board,\u201d said Paul Clancy, chair of the board of directors of Xilio Therapeutics. \u201cWith over 25 years of experience in oncology research and development, focused on translational medicine and clinical &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/xilio-therapeutics-appoints-akintunde-bello-ph-d-to-its-board-of-directors\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Xilio Therapeutics Appoints Akintunde Bello, Ph.D., to its Board of Directors&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-859274","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Xilio Therapeutics Appoints Akintunde Bello, Ph.D., to its Board of Directors - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/xilio-therapeutics-appoints-akintunde-bello-ph-d-to-its-board-of-directors\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Xilio Therapeutics Appoints Akintunde Bello, Ph.D., to its Board of Directors - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"WALTHAM, Mass., June 10, 2025 (GLOBE NEWSWIRE) &#8212; Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced the appointment of Akintunde (Tunde) Bello, Ph.D., to the company\u2019s board of directors. \u201cTunde is an accomplished leader with a strong track record of successfully developing novel therapies across a broad range of therapeutic areas, including several important cancer immunotherapies for anti-CTLA-4, PD-1 and T-cell engager through all stages of development, and I am thrilled to welcome him to the board,\u201d said Paul Clancy, chair of the board of directors of Xilio Therapeutics. \u201cWith over 25 years of experience in oncology research and development, focused on translational medicine and clinical &hellip; Continue reading &quot;Xilio Therapeutics Appoints Akintunde Bello, Ph.D., to its Board of Directors&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/xilio-therapeutics-appoints-akintunde-bello-ph-d-to-its-board-of-directors\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-06-10T20:33:42+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ2NjQyMSM2OTg0NTg4IzIyMDk4MDQ=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xilio-therapeutics-appoints-akintunde-bello-ph-d-to-its-board-of-directors\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xilio-therapeutics-appoints-akintunde-bello-ph-d-to-its-board-of-directors\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Xilio Therapeutics Appoints Akintunde Bello, Ph.D., to its Board of Directors\",\"datePublished\":\"2025-06-10T20:33:42+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xilio-therapeutics-appoints-akintunde-bello-ph-d-to-its-board-of-directors\\\/\"},\"wordCount\":1036,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xilio-therapeutics-appoints-akintunde-bello-ph-d-to-its-board-of-directors\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ2NjQyMSM2OTg0NTg4IzIyMDk4MDQ=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xilio-therapeutics-appoints-akintunde-bello-ph-d-to-its-board-of-directors\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xilio-therapeutics-appoints-akintunde-bello-ph-d-to-its-board-of-directors\\\/\",\"name\":\"Xilio Therapeutics Appoints Akintunde Bello, Ph.D., to its Board of Directors - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xilio-therapeutics-appoints-akintunde-bello-ph-d-to-its-board-of-directors\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xilio-therapeutics-appoints-akintunde-bello-ph-d-to-its-board-of-directors\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ2NjQyMSM2OTg0NTg4IzIyMDk4MDQ=\",\"datePublished\":\"2025-06-10T20:33:42+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xilio-therapeutics-appoints-akintunde-bello-ph-d-to-its-board-of-directors\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xilio-therapeutics-appoints-akintunde-bello-ph-d-to-its-board-of-directors\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xilio-therapeutics-appoints-akintunde-bello-ph-d-to-its-board-of-directors\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ2NjQyMSM2OTg0NTg4IzIyMDk4MDQ=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ2NjQyMSM2OTg0NTg4IzIyMDk4MDQ=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xilio-therapeutics-appoints-akintunde-bello-ph-d-to-its-board-of-directors\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Xilio Therapeutics Appoints Akintunde Bello, Ph.D., to its Board of Directors\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Xilio Therapeutics Appoints Akintunde Bello, Ph.D., to its Board of Directors - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/xilio-therapeutics-appoints-akintunde-bello-ph-d-to-its-board-of-directors\/","og_locale":"en_US","og_type":"article","og_title":"Xilio Therapeutics Appoints Akintunde Bello, Ph.D., to its Board of Directors - Market Newsdesk","og_description":"WALTHAM, Mass., June 10, 2025 (GLOBE NEWSWIRE) &#8212; Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced the appointment of Akintunde (Tunde) Bello, Ph.D., to the company\u2019s board of directors. \u201cTunde is an accomplished leader with a strong track record of successfully developing novel therapies across a broad range of therapeutic areas, including several important cancer immunotherapies for anti-CTLA-4, PD-1 and T-cell engager through all stages of development, and I am thrilled to welcome him to the board,\u201d said Paul Clancy, chair of the board of directors of Xilio Therapeutics. \u201cWith over 25 years of experience in oncology research and development, focused on translational medicine and clinical &hellip; Continue reading \"Xilio Therapeutics Appoints Akintunde Bello, Ph.D., to its Board of Directors\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/xilio-therapeutics-appoints-akintunde-bello-ph-d-to-its-board-of-directors\/","og_site_name":"Market Newsdesk","article_published_time":"2025-06-10T20:33:42+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ2NjQyMSM2OTg0NTg4IzIyMDk4MDQ=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/xilio-therapeutics-appoints-akintunde-bello-ph-d-to-its-board-of-directors\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/xilio-therapeutics-appoints-akintunde-bello-ph-d-to-its-board-of-directors\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Xilio Therapeutics Appoints Akintunde Bello, Ph.D., to its Board of Directors","datePublished":"2025-06-10T20:33:42+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/xilio-therapeutics-appoints-akintunde-bello-ph-d-to-its-board-of-directors\/"},"wordCount":1036,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/xilio-therapeutics-appoints-akintunde-bello-ph-d-to-its-board-of-directors\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ2NjQyMSM2OTg0NTg4IzIyMDk4MDQ=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/xilio-therapeutics-appoints-akintunde-bello-ph-d-to-its-board-of-directors\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/xilio-therapeutics-appoints-akintunde-bello-ph-d-to-its-board-of-directors\/","name":"Xilio Therapeutics Appoints Akintunde Bello, Ph.D., to its Board of Directors - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/xilio-therapeutics-appoints-akintunde-bello-ph-d-to-its-board-of-directors\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/xilio-therapeutics-appoints-akintunde-bello-ph-d-to-its-board-of-directors\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ2NjQyMSM2OTg0NTg4IzIyMDk4MDQ=","datePublished":"2025-06-10T20:33:42+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/xilio-therapeutics-appoints-akintunde-bello-ph-d-to-its-board-of-directors\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/xilio-therapeutics-appoints-akintunde-bello-ph-d-to-its-board-of-directors\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/xilio-therapeutics-appoints-akintunde-bello-ph-d-to-its-board-of-directors\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ2NjQyMSM2OTg0NTg4IzIyMDk4MDQ=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ2NjQyMSM2OTg0NTg4IzIyMDk4MDQ="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/xilio-therapeutics-appoints-akintunde-bello-ph-d-to-its-board-of-directors\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Xilio Therapeutics Appoints Akintunde Bello, Ph.D., to its Board of Directors"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/859274","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=859274"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/859274\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=859274"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=859274"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=859274"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}